Substance

ID:73126

Names and Identifiers
IUPAC name
(1S,2S,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
Synonyms
DocetaxelTaxotere
IUPAC Traditional name
(1S,2S,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
Registration numbers
CAS Number
Properties
Product Information
Salt Data
Free Base
Safety Information
Storage Condition
-20°C
Pharmacology Properties
Target
Microtubule Formation
Physical Property
Solubility
DMSO
Molecule Details
Research Area: Solid tumours
Biological Activity:
Docetaxel (Taxotere) is a semi-synthetic, second-generation taxane, with anti-neoplastic application for the treatment of breast, ovarian, and non-small cell lung cancer. [1]Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. The overall cells mean IC50 for docetaxel treatment was 4.67 nM,similar to IC50 values observed across the NCI60 panel of human tumor cell lines, which exhibit a mean docetaxel IC50 of 23.4 nM, with a range of 0.31–100 nM. [2]This agent also inhibits pro-angiogenic factors such as VEGF and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. [3] 
Molecular Spectra
No Data Available
Click here to submit data
References
•  James W. Watters et al. PNAS.2004 August 10;101(32):11809-11814